No Data
Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Not Lagging Market On Growth Or Pricing
China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.
In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.
This week, an additional 29 companies have announced! TIGERMED and several other stocks disclosed repurchase and shareholding refinancing plans, with a list of related A-shares overview.
① The number of A-share listed companies receiving special loan support continues to expand. According to incomplete Statistics, as of the time of writing, 29 listed companies have disclosed information related to share repurchase and increased shareholding for re-loan this week (see attached table); ② TIGERMED received the highest amount of special loan support, totaling no more than 0.7 billion yuan.
TIGERMED (300347.SZ): has obtained the commitment letter for Share Buyback loans from Financial Institutions.
Glory Financial reported on January 8 that TIGERMED (300347.SZ) announced it has recently received a "Loan Commitment Letter" issued by the Hangzhou Branch of Bank Of China Limited. The main content is as follows: 1. Loan amount: not exceeding ¥700,000,000 (in words: seven hundred million yuan), which is no more than 70% of the maximum repurchase amount; 2. Loan term: not exceeding 36 months; 3. Loan usage: specifically for the "TIGERMED" (stock code 300347) Share Buyback. The actual loan amount and the total amount of repurchased funds shall not exceed the upper limit of this repurchase plan.
Tigermed (300347.SZ): has repurchased 0.42% of shares accumulated.
Glory Capital, January 3rd丨TIGERMED (300347.SZ) announced that as of December 31, 2024, the company's share repurchase special securities account has cumulatively repurchased 3,655,200 shares of the company through centralized bidding trading, accounting for 0.4226% of the company's total share capital and 0.4927% of the company's total A-share capital. The highest Fill Price was 55.30 yuan/share, the lowest Fill Price was 48.17 yuan/share, and the total amount of the transaction was 0.191 billion yuan (excluding trading costs).
FRONTAGE (01521.HK) was increased shareholding by Hongkong Tigermed Co., Limited by 1.064 million shares.
On January 3, Glory Holdings reported that according to the latest equity disclosure data from the Stock Exchange, on December 31, 2024, FRONTAGE (01521.HK) was increased by Hongkong Tigermed Co., Limited in the market, acquiring 1.064 million shares at an average price of HKD 1.773 per share, involving approximately HKD 1.1865 million. After the shareholding increase, the latest number of shares held by Hongkong Tigermed Co., Limited is 1,079,664,090 shares, with the shareholding ratio rising from 52.98% to 53.04%.
No Data
